Business Context and Reporting Period
Allogene Therapeutics, Inc. filed this Form 8-K on June 7, 2023, reporting clinical data presented on June 3, 2023, at the ASCO Annual Meeting. The update concerns ALLO-501 and ALLO-501A, allogeneic CD19-directed CAR T-cell product candidates, in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Key Clinical Metrics
The updated Phase 1 ALPHA/ALPHA2 analysis covered 12 CAR T-naïve patients treated with a single dose of ALLO-501/501A manufactured using the Alloy process and the Phase 2 FCA90 lymphodepletion regimen. All patients had at least six months of follow-up as of the April 20, 2023 data cutoff.
| Measure | Result |
|---|---|
| Overall response rate | 8 of 12 patients (67%) |
| Complete response rate | 7 of 12 patients (58%) |
| Complete response at six months | 5 of 12 patients (42%) |
| Median duration of response | 23.1 months |
| Patients remaining in remission for more than 24 months | 3 patients |
| Longest reported remission | More than 31 months |
Among the five patients in complete response at six months, four (80%) remained in complete response; the fifth experienced disease progression at 24 months.
Safety and Other Findings
Across 33 CAR T-naïve LBCL patients treated with Alloy-process ALLO-501/501A at any dose or lymphodepletion schedule, no Grade 3 or greater cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease was reported. In the 12-patient Phase 2-regimen group, reported events included cytokine release syndrome in 4 patients (33%), neurotoxicity in 4 (33%), infusion-related reactions in 8 (67%), infections in 8 (67%), and Grade 3 or greater prolonged cytopenia in 2 (17%).
Outlook, Risks, and Unusual Items
Allogene stated that it is enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in LBCL and expects to complete enrollment in the first half of 2024. The filing provides no revenue, earnings, cash flow, margin, debt, or liquidity figures because it is a clinical-development update rather than a financial-results filing.
Management cautioned that the Phase 1 data are limited, may change with additional follow-up, and may not be validated in later-stage trials. Key risks include clinical or regulatory delays, patient-enrollment challenges, adverse effects, manufacturing difficulties, intellectual-property issues, FDA disagreement with clinical plans, financing needs, and the possibility that safety or efficacy may not support approval or commercialization. Comparisons with autologous CAR T therapies may not be directly interpretable because of differences in trial design, populations, follow-up, and products.
Facts Investors Should Verify
- Whether the Phase 2 ALPHA2 trial completes enrollment in the first half of 2024 as projected.
- Whether the observed response durability and safety profile are reproduced in the larger Phase 2 population.
- Enrollment status, protocol details, and subsequent efficacy and safety updates for ALPHA2.
- Regulatory feedback and the requirements for any potentially pivotal development pathway.
- Cash resources, operating runway, financing requirements, and other financial metrics in the company’s quarterly and annual filings.
- Whether later data confirm the manufacturing, durability, and comparative-treatment claims associated with the Alloy process and allogeneic CAR T candidates.